These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 24520856

  • 1. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
    Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T.
    J Med Chem; 2014 Mar 27; 57(6):2582-8. PubMed ID: 24520856
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
    Beumer JH, Eiseman JL, Parise RA, Florian JA, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2008 Aug 27; 62(3):457-64. PubMed ID: 18008070
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
    Besnard T, Renée N, Etienne-Grimaldi MC, François E, Milano G.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul 01; 870(1):117-20. PubMed ID: 18562256
    [Abstract] [Full Text] [Related]

  • 7. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
    Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2011 Feb 01; 67(2):421-30. PubMed ID: 20443002
    [Abstract] [Full Text] [Related]

  • 8. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.
    PLoS Med; 2017 Sep 01; 14(9):e1002382. PubMed ID: 28880867
    [Abstract] [Full Text] [Related]

  • 9. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
    Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL.
    Cancer Chemother Pharmacol; 2015 Oct 01; 76(4):803-11. PubMed ID: 26321472
    [Abstract] [Full Text] [Related]

  • 10. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
    Eliopoulos N, Cournoyer D, Momparler RL.
    Cancer Chemother Pharmacol; 1998 Oct 01; 42(5):373-8. PubMed ID: 9771951
    [Abstract] [Full Text] [Related]

  • 11. Tetrahydrouridine, cytidine analogues, and hemoglobin F.
    DeSimone J, Heller P, Molokie RE, Hall L, Zwiers D.
    Am J Hematol; 1985 Mar 01; 18(3):283-8. PubMed ID: 2579548
    [Abstract] [Full Text] [Related]

  • 12. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase.
    Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ.
    J Med Chem; 1986 Aug 01; 29(8):1374-80. PubMed ID: 3735306
    [Abstract] [Full Text] [Related]

  • 13. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
    Tang Z, Liu L, Borlak J.
    Clin Epigenetics; 2023 May 19; 15(1):89. PubMed ID: 37208732
    [Abstract] [Full Text] [Related]

  • 14. On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
    Wentworth DF, Wolfenden R.
    Biochemistry; 1975 Nov 18; 14(23):5099-105. PubMed ID: 53069
    [Abstract] [Full Text] [Related]

  • 15. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
    Laliberté J, Marquez VE, Momparler RL.
    Cancer Chemother Pharmacol; 1992 Nov 18; 30(1):7-11. PubMed ID: 1375134
    [Abstract] [Full Text] [Related]

  • 16. The 1.48 A resolution crystal structure of the homotetrameric cytidine deaminase from mouse.
    Teh AH, Kimura M, Yamamoto M, Tanaka N, Yamaguchi I, Kumasaka T.
    Biochemistry; 2006 Jun 27; 45(25):7825-33. PubMed ID: 16784234
    [Abstract] [Full Text] [Related]

  • 17. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.
    Ebrahem Q, Mahfouz RZ, Ng KP, Saunthararajah Y.
    Oncotarget; 2012 Oct 27; 3(10):1137-45. PubMed ID: 23087155
    [Abstract] [Full Text] [Related]

  • 18. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
    Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J, Saunthararajah Y.
    Blood; 2012 Feb 02; 119(5):1240-7. PubMed ID: 22160381
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds.
    McCormack JJ, Marquez VE, Liu PS, Vistica DT, Driscoll JS.
    Biochem Pharmacol; 1980 Mar 01; 29(5):830-2. PubMed ID: 20227965
    [No Abstract] [Full Text] [Related]

  • 20. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
    Voytek P, Beisler JA, Abbasi MM, Wolpert-DeFilippes MK.
    Cancer Res; 1977 Jul 01; 37(7 Pt 1):1956-61. PubMed ID: 67884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.